Screener
AbCellera Biologics Inc. ABCL Total Equity
Total Equity at other companies
Other financials
Where this comes from
Reported directly by AbCellera Biologics Inc. in its filing.
Tagged under the XBRL concept us-gaap:StockholdersEquity.
The source filing: AbCellera Biologics Inc.’s 10-Q, filed August 5, 2026. Open the filing →
- Filed
- Aug 5, 2026, 4:28 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001703057-26-000046
FAQ
- What is AbCellera Biologics Inc.'s total equity?
- AbCellera Biologics Inc. (ABCL) reported total equity of $896.02M in Q2 2026.
- How has AbCellera Biologics Inc.'s total equity changed year-over-year?
- AbCellera Biologics Inc.'s total equity decreased by 11.0% year-over-year, from $1.01B to $896.02M.
- What is the long-term trend for AbCellera Biologics Inc.'s total equity?
- Over 5 years (2020 to 2025), AbCellera Biologics Inc.'s total equity has grown at a 3.1% compound annual growth rate (CAGR), from $830.51M to $966.9M.
- What does total equity mean?
- Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.
Ask your AI about AbCellera Biologics Inc.'s total equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude